Technology Appraisal Committee Meeting Committee C

Minutes: Confirmed

Date and Time: Wednesday 12 October 2016, 10:00 – 16:15

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Professor Andrew Stevens  Present for all notes
2. Professor Andrew Renehan  Present for all notes
3. Professor Andrea Manca  Present for notes 09 to 13
4. Dr Anna O’Neill  Present for all notes
5. David Chandler  Present for all notes
6. Vice-Chair Professor Eugene Milne  Present for all notes
7. Dr Iain Miller  Present for all notes
8. Dr Judith Wardle  Present for all notes
9. Mr Kamal Balakrishnan  Present for all notes
10. Professor Kathryn Abel  Present for all notes
11. Prof Matt Stevenson  Present for notes 01 to 08
12. Mr Michael Chambers  Present for all notes
13. Dr Nigel Langford  Present for all notes
14. Dr Prithwiraj Das  Present for all notes
15. Dr Paul Tappenden  Present for all notes
16. Dr Peter Selby  Present for all notes
17. Professor Rachel Elliott  Present for all notes
18. Professor Robert Walton  Present for all notes
19. Professor Stephen O’Brien  Present for all notes

In attendance:

Meindert Boysen  Programme Director, National Institute for Health and Care Excellence  Present for all notes

Dr Frances Sutcliffe  Associate Director, National Institute for Health and Care Excellence  Present for all notes

Stephanie Yates  Project Manager, National Institute for Health and Care Excellence  Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Present for notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Ekeledo</td>
<td>Administrator, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Emily Richards</td>
<td>Assistant Project Manager, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Stuart Wood</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 04 to 08</td>
</tr>
<tr>
<td>Raisa Sidhu</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>Present for notes 04 to 08</td>
</tr>
<tr>
<td>Hamish Lunagaria</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 09 to 13</td>
</tr>
<tr>
<td>Joanne Holden</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 09 to 13</td>
</tr>
<tr>
<td><strong>Non-public observers:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debra Fayter</td>
<td>ERG representative</td>
<td>Present for notes 04 to 07</td>
</tr>
<tr>
<td>Nasuh Buyukkaramikli</td>
<td>ERG representative</td>
<td>Present for notes 04 to 07</td>
</tr>
<tr>
<td>Robert Wolff</td>
<td>ERG representative</td>
<td>Present for notes 04 to 07</td>
</tr>
<tr>
<td>Steve Edwards</td>
<td>ERG representative</td>
<td>Present for notes 09 to 12</td>
</tr>
<tr>
<td>Peter Cain</td>
<td>ERG representative</td>
<td>Present for notes 09 to 12</td>
</tr>
<tr>
<td>Vicky Wakefield</td>
<td>ERG representative</td>
<td>Present for notes 09 to 12</td>
</tr>
<tr>
<td>Dr Matthew Streetly</td>
<td>Clinical expert</td>
<td>Present for notes 04 to 07 and 09 to 12</td>
</tr>
<tr>
<td>Dr Neil Rabin</td>
<td>Clinical expert</td>
<td>Present for notes 04 to 07</td>
</tr>
<tr>
<td>Mr Alan Chant</td>
<td>Patient Expert</td>
<td>Present for notes 04 to 07 and 09 to 12</td>
</tr>
<tr>
<td>Mr Eric Low</td>
<td>Patient Expert</td>
<td>Present for notes 04 to 07 and 09 to 12</td>
</tr>
<tr>
<td>Dr Karthik Ramasamy</td>
<td>Clinical expert</td>
<td>Present for notes 09 to 12</td>
</tr>
<tr>
<td>Kate Moring</td>
<td>NICE observer</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Hannah Strickland (PIP)</td>
<td>NICE observer</td>
<td>Present for notes 04 to 07</td>
</tr>
<tr>
<td>Nathan Ashurst</td>
<td>NICE observer</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Luan Linden-Phillips</td>
<td>HSRIC Observer</td>
<td>Present for all notes</td>
</tr>
</tbody>
</table>
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338) and carfilzomib for treated multiple myeloma.

2. Apologies were received from Gail Coster

Any other Business

3. None

Appraisal of pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338) [ID985]

Part 1 – Open session

4. The Chair welcomed the invited experts Dr Matthew Streetly, Dr Neil Rabin, Mr Alan Chant and Mr Eric Low to the meeting and they introduced themselves to the Committee.

5. The Chair welcomed company representatives from Celgene to the meeting.

6. The Chair asked all Committee members to declare any relevant interests

6.1. Professor Andrew Renehan, Dr Anna O’Neill, David Chandler, Professor Eugene Milne, Dr Iain Miller, Dr Judith Wardle, Mr Kamal Balakrishnan Professor Kathryn Abel, Prof Matt Stevenson, Mr Michael Chambers, Dr Nigel Langford, Dr Prithwiraj Das, Dr Paul Tappenden, Dr Peter Selby Professor Rachel Elliott, Professor Robert Walton and Professor Stephen O’Brien all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338).

7. The Chair asked all NICE Staff to declare any relevant interests.

7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pomalidomide with dexamethasone for treating relapsed and refractory multiple
8. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338).

8.2. Dr Matthew Streetly declared a personal non-specific financial interest he has attended Advisory Board meeting for Celgene
8.2.1. It was agreed that this declaration would not prevent Dr Matthew Streetly from participating in this section of the meeting

8.3. Dr Neil Rabin declared a personal non-specific financial interest he has received honorarium from Celgene
8.3.1. It was agreed that this declaration would not prevent Dr Neil Rabin from participating in this section of the meeting

8.4. Mr Eric Low declared a non personal non-specific financial interest. Myeloma UK has been paid honorarium directly from Celgene
8.4.1. It was agreed that this declaration would not prevent Mr Eric Low from participating in this section of the meeting

9. The Chair introduced the lead team, Dr Iain Miller, Professor Rachel Elliott and Mr David Chandler who gave presentations on the clinical effectiveness and cost effectiveness of pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338).

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. The Committee continued to discuss the clinical and cost effectiveness of pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338)
13.1. The committee decision was based on consensus.

14. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of carfilzomib for treated multiple myeloma [ID934]

Part 1 – Open session

15. The Vice-Chair welcomed the invited experts: Dr Matthew Streetly, Dr Karthik Ramasamy, Mr Eric Low and Mr Alan Chant to the meeting and they introduced themselves to the Committee.

16. The Vice-Chair welcomed company representatives from Amgen to the meeting.

17. The Vice-Chair asked all Committee members to declare any relevant interests

17.1. Professor Andrew Stevens, Professor Andrea Manca, Professor Andrew Renehan, Dr Anna O’Neill, David Chandler, Dr Iain Miller, Dr Judith Wardle, Mr Kamal Balakrishnan Professor Kathryn Abel, Mr Michael Chambers, Dr Nigel Langford, Dr Prithviraj Das, Dr Paul Tappenden, Dr Peter Selby, Professor Rachel Elliott, Professor Robert Walton and Professor Stephen O’Brien all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of carfilzomib for treated multiple myeloma.

17.2. Professor Matt Stevenson declared a personal specific financial interest and is excluded from the committee. He has received payment from Onyx who previously held the rights to carfilzomib to advise on their STA submission. Onyx were then taken over by Amgen and he has done no further work.

18. The Vice-Chair asked all NICE Staff to declare any relevant interests.

18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Carfilzomib for treated multiple myeloma.

19. The Vice-Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of carfilzomib for treated multiple myeloma.
20. The Vice-Chair introduced the lead team, Professor Andrea Manca, Dr Peter Selby and Mr David Chandler who gave presentations on the clinical effectiveness and cost effectiveness of carfilzomib for treated multiple myeloma

21. The Vice-Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

22. The Vice-Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

23. The Vice-Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

24. The Committee continued to discuss the clinical and cost effectiveness of carfilzomib for treated multiple myeloma.

24.1. The committee decision was based on consensus.

25. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

26. Wednesday 9 November 2016, 10:00 to 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.